Pharmacokinetics of Lonidamine after oral administration in cancer patients. 1984

J G Besner, and R Leclaire, and P R Band, and M Deschamps, and A J De Sanctis, and B Catanese

The pharmacokinetics of Lonidamine has been studied in cancer patients after single and chronic oral administrations. After single administration the plasma kinetics are highly variable, while the dose eliminated in the urine is over 70% in all subjects. This suggests an active but interindividually variable first-pass effect. After repeated administrations, both the residual plasma concentration before administration (C infinity min) and that obtained after drug intake (C infinity max) have been studied. The C infinity max values range from 4.5 to 25 micrograms/ml and C infinity min values from 0.4 to 7 micrograms/ml. In patients where a therapeutic response was noted, a mean value of 2.98 micrograms/ml for C infinity min was measured. In patients unresponsive to drug therapy the mean C infinity min was 1.5 micrograms/ml.

UI MeSH Term Description Entries
D007191 Indazoles A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES. Indazole
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000042 Absorption The physical or physiological processes by which substances, tissue, cells, etc. take up or take in other substances or energy.

Related Publications

J G Besner, and R Leclaire, and P R Band, and M Deschamps, and A J De Sanctis, and B Catanese
April 1991, Seminars in oncology,
J G Besner, and R Leclaire, and P R Band, and M Deschamps, and A J De Sanctis, and B Catanese
January 1991, Cancer chemotherapy and pharmacology,
J G Besner, and R Leclaire, and P R Band, and M Deschamps, and A J De Sanctis, and B Catanese
March 1990, Leukemia,
J G Besner, and R Leclaire, and P R Band, and M Deschamps, and A J De Sanctis, and B Catanese
December 2020, Journal of pain & palliative care pharmacotherapy,
J G Besner, and R Leclaire, and P R Band, and M Deschamps, and A J De Sanctis, and B Catanese
January 1984, European journal of respiratory diseases. Supplement,
J G Besner, and R Leclaire, and P R Band, and M Deschamps, and A J De Sanctis, and B Catanese
January 1984, Oncology,
J G Besner, and R Leclaire, and P R Band, and M Deschamps, and A J De Sanctis, and B Catanese
January 1981, Chemotherapy,
J G Besner, and R Leclaire, and P R Band, and M Deschamps, and A J De Sanctis, and B Catanese
January 1996, Cancer chemotherapy and pharmacology,
J G Besner, and R Leclaire, and P R Band, and M Deschamps, and A J De Sanctis, and B Catanese
January 1985, Polski tygodnik lekarski (Warsaw, Poland : 1960),
J G Besner, and R Leclaire, and P R Band, and M Deschamps, and A J De Sanctis, and B Catanese
January 1986, Progress in neuro-psychopharmacology & biological psychiatry,
Copied contents to your clipboard!